COGNICURRENT

Feb 4 • 07:00 UTC • 🇩🇰 Denmark • Politiken

Sales of migraine medication drives Lundbeck's revenue growth

Danish pharmaceutical company Lundbeck has increased its revenue by 13% to 24.6 billion kroner in 2025, driven by the success of medications Vyepti and Rexulti, although net profit has not kept pace with sales growth.

#lundbeck #pharmaceutical #revenue #vyepti #rexulti

Read Original Back to Feed

📡 Similar Coverage

🇩🇰 Denmark Feb 3 • 17:17 UTC

Novo lander growth at six percent with annual report

Politiken

🇩🇪 Germany Feb 6 • 13:02 UTC

Business Ticker: Stroke Medication Becomes New Hope for Bayer - the Stock Market Reacts

FAZ

🇩🇰 Denmark Feb 3 • 17:17 UTC

Dismal prediction: If Novo is correct, 2026 could be the worst year of this millennium

Politiken

🇩🇪 Germany Feb 4 • 13:17 UTC

"The market is relatively saturated - we see no big growth prospects anymore"

Die Welt

🇬🇷 Greece Feb 4 • 08:35 UTC

Novo Nordisk: 18% 'plunge' in stocks after the 'cold shower' for 2026 forecasts

Naftemporiki

🇩🇰 Denmark Feb 4 • 16:26 UTC

Novo Nordisk has never made as much money as now – so why is the stock diving?

Politiken